Cargando…
Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
BACKGROUND: Colorectal cancer (CRC) remains a major public concern. While conventional chemotherapeutic regimens have proved useful against advanced/metastatic diseases, progresses are to be made to effectively cure the large portion of patients not benefiting from these treatments. One direction to...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721000/ https://www.ncbi.nlm.nih.gov/pubmed/26791256 http://dx.doi.org/10.1186/s12967-016-0765-4 |
_version_ | 1782411157483552768 |
---|---|
author | Bounaix Morand du Puch, Christophe Nouaille, Michelle Giraud, Stéphanie Labrunie, Anaïs Luce, Sandrine Preux, Pierre-Marie Labrousse, François Gainant, Alain Tubiana-Mathieu, Nicole Le Brun-Ly, Valérie Valleix, Denis Guillaudeau, Angélique Mesturoux, Laura Coulibaly, Béma Lautrette, Christophe Mathonnet, Muriel |
author_facet | Bounaix Morand du Puch, Christophe Nouaille, Michelle Giraud, Stéphanie Labrunie, Anaïs Luce, Sandrine Preux, Pierre-Marie Labrousse, François Gainant, Alain Tubiana-Mathieu, Nicole Le Brun-Ly, Valérie Valleix, Denis Guillaudeau, Angélique Mesturoux, Laura Coulibaly, Béma Lautrette, Christophe Mathonnet, Muriel |
author_sort | Bounaix Morand du Puch, Christophe |
collection | PubMed |
description | BACKGROUND: Colorectal cancer (CRC) remains a major public concern. While conventional chemotherapeutic regimens have proved useful against advanced/metastatic diseases, progresses are to be made to effectively cure the large portion of patients not benefiting from these treatments. One direction to improve response rates is to develop chemosensitivity and resistance assays (CSRAs) efficiently assisting clinicians in treatment selection process, an already long preoccupation of oncologists and researchers. Several methods have been described to this day, none achieving yet sufficient reliability for recommended use in the clinical routine. METHODS: We led a pilot study on 19 metastatic CRC patients evaluating capacity of the Oncogramme, a standardized process using tumor ex vivo models, to provide chemosensitivity profiles and predict clinical outcome of patients receiving standard CRC chemotherapeutics. Oncogramme responses were categorized according to the method of percentiles to assess sensitivity, specificity and concordance. RESULTS: We report from a primary analysis a success rate of 97.4 %, a very good sensitivity (84.6 %), a below-average specificity (33.3 %), along with a global agreement of 63.6 % and a concordance between Oncogramme results and patients’ responses (Kappa coefficient) of 0.193. A supplementary analysis, focusing on CRC patients with no treatment switch over a longer time course, demonstrated improvement in specificity and concordance. CONCLUSIONS: Results establish feasibility and usefulness of the Oncogramme, prelude to a larger-scale trial. Advantages and drawbacks of the procedure are discussed, as well as the place of CSRAs within the future arsenal of methods available to clinicians to individualize treatments and improve patient prognosis. Trial registration: ClinicalTrials.gov database, registration number: NCT02305368 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-0765-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4721000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47210002016-01-22 Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer Bounaix Morand du Puch, Christophe Nouaille, Michelle Giraud, Stéphanie Labrunie, Anaïs Luce, Sandrine Preux, Pierre-Marie Labrousse, François Gainant, Alain Tubiana-Mathieu, Nicole Le Brun-Ly, Valérie Valleix, Denis Guillaudeau, Angélique Mesturoux, Laura Coulibaly, Béma Lautrette, Christophe Mathonnet, Muriel J Transl Med Research BACKGROUND: Colorectal cancer (CRC) remains a major public concern. While conventional chemotherapeutic regimens have proved useful against advanced/metastatic diseases, progresses are to be made to effectively cure the large portion of patients not benefiting from these treatments. One direction to improve response rates is to develop chemosensitivity and resistance assays (CSRAs) efficiently assisting clinicians in treatment selection process, an already long preoccupation of oncologists and researchers. Several methods have been described to this day, none achieving yet sufficient reliability for recommended use in the clinical routine. METHODS: We led a pilot study on 19 metastatic CRC patients evaluating capacity of the Oncogramme, a standardized process using tumor ex vivo models, to provide chemosensitivity profiles and predict clinical outcome of patients receiving standard CRC chemotherapeutics. Oncogramme responses were categorized according to the method of percentiles to assess sensitivity, specificity and concordance. RESULTS: We report from a primary analysis a success rate of 97.4 %, a very good sensitivity (84.6 %), a below-average specificity (33.3 %), along with a global agreement of 63.6 % and a concordance between Oncogramme results and patients’ responses (Kappa coefficient) of 0.193. A supplementary analysis, focusing on CRC patients with no treatment switch over a longer time course, demonstrated improvement in specificity and concordance. CONCLUSIONS: Results establish feasibility and usefulness of the Oncogramme, prelude to a larger-scale trial. Advantages and drawbacks of the procedure are discussed, as well as the place of CSRAs within the future arsenal of methods available to clinicians to individualize treatments and improve patient prognosis. Trial registration: ClinicalTrials.gov database, registration number: NCT02305368 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-0765-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-12 /pmc/articles/PMC4721000/ /pubmed/26791256 http://dx.doi.org/10.1186/s12967-016-0765-4 Text en © Bounaix Morand du Puch et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Bounaix Morand du Puch, Christophe Nouaille, Michelle Giraud, Stéphanie Labrunie, Anaïs Luce, Sandrine Preux, Pierre-Marie Labrousse, François Gainant, Alain Tubiana-Mathieu, Nicole Le Brun-Ly, Valérie Valleix, Denis Guillaudeau, Angélique Mesturoux, Laura Coulibaly, Béma Lautrette, Christophe Mathonnet, Muriel Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer |
title | Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer |
title_full | Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer |
title_fullStr | Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer |
title_full_unstemmed | Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer |
title_short | Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer |
title_sort | chemotherapy outcome predictive effectiveness by the oncogramme: pilot trial on stage-iv colorectal cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721000/ https://www.ncbi.nlm.nih.gov/pubmed/26791256 http://dx.doi.org/10.1186/s12967-016-0765-4 |
work_keys_str_mv | AT bounaixmoranddupuchchristophe chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT nouaillemichelle chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT giraudstephanie chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT labrunieanais chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT lucesandrine chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT preuxpierremarie chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT labroussefrancois chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT gainantalain chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT tubianamathieunicole chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT lebrunlyvalerie chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT valleixdenis chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT guillaudeauangelique chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT mesturouxlaura chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT coulibalybema chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT lautrettechristophe chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer AT mathonnetmuriel chemotherapyoutcomepredictiveeffectivenessbytheoncogrammepilottrialonstageivcolorectalcancer |